
|Articles|June 21, 2004
Drug provides relief to those with overactive bladder
The FDA recently approved trospium (Sanctura, Indevus Pharmaceuticals/Odyssey Pharmaceuticals) for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency. The product launch of trospium is expected to take place during the third quarter of 2004.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FAQ: The Medicare GLP-1 Bridge—What Independent Pharmacists Need to Know
2
Grocery Pharmacy Conglomerate to Pay $40 Million for Violating False Claims Act
3
HHS Claims ACIP Cannot Meet for Flu Season Due to Ongoing Legal Battle
4
US Controlled Substance Market Expected to Grow $21 Billion by 2035
5




































